References
- 1. Pakos EE, Grimer RJ, Peake D et al. The ‘other’ bone sarcomas: prognostic factors and outcomes of spindle cell sarcomas of bone. J Bone Joint Surg Br. 2011; 93:1271–1278.
- 2. Larrier NA, Czito BG, Kirsch DG. Radiation therapy for soft tissue sarcoma: indications and controversies for neoadjuvant therapy, adjuvant therapy, intraoperative radiation therapy, and brachytherapy. Surg Oncol Clin N Am. 2016; 25:841–860.10.1016/j.soc.2016.05.012
- 3. Bramwell VHC, Steward WP, Nooij M. Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. Journal of Clinical Oncology. October 1999; 17,10:3260-3269.
- 4. Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol. 2017; 9(6):415–429.10.1177/1758834017705588
- 5. Wei Z, Li L, Xu XY. A case of recurrent malignant fibrous histiocytoma with marked response to combined chemotherapy with gemcitabine and carboplatin. Arch Med Sci. 2014 Oct 27; 10(5):1057–1060.
- 6. Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of highrisk, high-grade, sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006; 24: 619–625.